Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond

Overview of attention for article published in Seminars in Immunopathology, September 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#45 of 600)
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter: 8 X users

patent: 10 patents

Readers on

mendeley: 146 Mendeley

So far, Altmetric has seen 10 patents that reference this research output.

Fused imidazole derivatives as AHR antagonists

Grant US-12570638-B2

United States of America

10 Mar 2026

Dosing Regimens for IDO Inhibitors

Application JP-2022543062-A

Japan

07 Oct 2022

Dosing regimen for IDO inhibitors

Application CN-114502196-A

China

13 May 2022

BIOMARKERS RELATED TO IMMUNE CHECKPOINT INHIBITOR THERAPY AND METHODS OF USING THE SAME

Application WO-2022081649-A1

World Intellectual Property Organisation (WIPO)

21 Apr 2022

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 6 additional patents.